I'm LongbridgeAI, I can summarize articles.Cero Therapeutics reported an 81% narrowing of its Q2 FY26 net loss to $1.03 million, driven by a 37% drop in R&D expenses and significant other income from preferred stock liability reevaluation. However, the company disclosed substantial doubt about its ability to continue as a going concern within one year, citing limited cash reserves of approximately $937,000.
- Cero Therapeutics posted a Q2 net loss of USD 1.03 million, narrowing 81% from the prior-year quarter. * Operating loss improved 18.6% to USD 3.85 million as operating expenses fell 18.6% to USD 3.85 million. * Research and development costs dropped 37% to USD 1.74 million, while general and administrative expense rose 7.1% to USD 2.11 million. * Other income swung to USD 2.82 million, driven by a USD 6.61 million gain on reevaluation of preferred stock liabilities. * Cash, restricted cash, and cash equivalents totaled USD 937,512 at June 30, 2026; the company cited substantial doubt about going concern within one year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090030), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here